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An ELISA  protocol  for  plasma  oxytocin  in  phocid  seals  was  validated.
Sample  handling  protocols  for  accurately  detecting  plasma  oxytocin  were  compared.
Concentrations  detected  in  raw  plasma  varied  signiﬁcantly  with  vacutainer  type.
Concentrations  detected  in extracted  plasma  were  unaffected  by  vacutainer  type.
Capture  and  restraint  protocol  affected  concentrations  detected  in raw  plasma.
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Background:  The  neuropeptide  oxytocin  is  increasingly  the  focus  of  many  studies  investigating  human
and  animal  social  behaviours  and  diseases.  However,  interpretation  and  comparison  of results  is made
difﬁcult by  a  lack  of consistent  methodological  approaches  towards  analysing  this  hormone.
New  method:  This study  determined  the sample  collection  and  analysis  protocols  that  cause  the  least
amounts  of protocol  dependant  variation  in plasma  oxytocin  concentrations  detected  by  ELISA.  The  effect
of vacutainer  type,  sample  extraction  prior  to analysis  and  capture  and  restraint  protocol  were  investi-
gated  while  validating  an  assay  protocol  for two novel  species,  grey  seals  (Halichoerus  grypus)  and  harbour
seals  (Phoca  vitulina).
Results:  Where  samples  are  extracted  prior  to  analysis,  vacutainer  type  (EDTA  mean:  8.25  ±  0.56  pg/ml,
heparin  mean:  8.25  ±  0.62  pg/ml,  p =  0.82),  time  taken  to  obtain  a sample  and  restraint  protocol  did
not  affect  the concentration  of oxytocin  detected.  However,  concentrations  of  oxytocin  detected  in raw
plasma  samples  were  signiﬁcantly  higher  than  those  in  extracted  samples,  and varied  signiﬁcantly  with
vacutainer  type  (EDTA  mean:  534.4  ±  43.7  pg/ml,  heparin  mean:  300.9  ± 19.6  pg/ml,  p  < 0.001)  and  cap-
ture  and  restraint  methodology.  There  was  no  relationship  between  oxytocin  concentrations  detected  in
raw  and  extracted  plasma  (p  = 0.25).
Comparison  with  existing  method(s):  Over  half  the  reviewed  published  studies  analysing  plasma  oxytocin
use  raw  plasma  and  different  vacutainer  types  are  used  without  consistency  or justiﬁcation  through-out
the  literature.
Conclusions:  We  caution  that  studies  using  raw  plasma  are  likely  to over  estimate  oxytocin  concentrations,
cannot  be used  to accurately  infer  true  values  via  correlations  and  are  susceptible  to  variation  according
vacutainer  type. This is an open-access article distributed under the terms of the Creative
ommons Attribution License, which permits unrestricted use, distribution and
eproduction in any medium, provided the original author and source are credited.
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1. Introduction
Oxytocin is a neuropeptide crucial for initiating and modu-
lating maternal and social behaviour across vertebrate animals
(Gimpl and Fahrenholz, 2001). Produced in the paraventricular
(PVN) and supraoptic nuclei (SON) of the hypothalamus, oxytocin
is stored in the posterior pituitary gland until its release is triggered
by a variety of stimuli, including scent, sight, touch and sound
of a dependant infant or social partner (Uvnäs-Moberg, 1998;
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eumann, 2008; MacDonald and MacDonald, 2010). Oxytocin is
eleased both centrally into the brain and peripherally into circu-
ation (Neumann and Landgraf, 2012) and it promotes care-giving
nd pro-social behaviours (Kosfeld et al., 2005; Ross and Young,
009) by providing a physiological reward for their expression by
ctivating reward and pleasure pathways in the brain (Baskerville
nd Douglas, 2010).
While its role in the physiology of parturition and lactation has
ong been known (Dale, 1906), oxytocin’s effects on behaviour are
till being explored. Studies looking to investigate peripheral lev-
ls of the hormone in relation to both animal and human behaviour
ave increased throughout the 21st century. In recent years there
ave been many studies examining possible links between oxytocin
nd a range of human psychological conditions, their causes and
reatment including post-partum depression (Levine et al., 2007;
eldman et al., 2010a; Skrundz et al., 2011), anxiety (Hoge et al.,
012; Weisman et al., 2013), autism (Modahl et al., 1998; Hollander
t al., 2003; El-Masry et al., 2010), depression (Scantamburlo et al.,
007; Holt-Lunstad et al., 2011), stress (Heinrichs et al., 2003;
rippo et al., 2009), anorexia nervosa (Hoffman et al., 2012) and
uicidal behaviour (Deisenhammer et al., 2012). Oxytocin has also
een used to investigate social and reproductive behaviour and
hysiology in a variety of domestic and laboratory mammalian
pecies such as dogs (Odendaal and Meintjes, 2003), sheep (Lévy
t al., 1995), primates (Amico et al., 1990; Maestripieri et al., 2009),
ice (McCarthy, 1990), voles (Bales et al., 2007) and rats (Popik
t al., 1992). However plasma oxytocin concentrations have never
een determined in any mammalian species outside of laboratory,
omestic or primate species, and the current study reports for the
rst time data from studies conducted on two species of phocis seals
he grey seal (Halichoerus grypus)  and harbour seal (Phoca vitulina).
Oxytocin has been assayed in various substrates including saliva
Carter et al., 2007; Feldman et al., 2010a,b), urine (Nagasawa et al.,
009; Moscovice and Ziegler, 2012; Crockford et al., 2013), cerebro-
pinal ﬂuid (Devarajan and Rusak, 2004; Martínez-Lorenzana et al.,
008), and milk (Leake et al., 1981; Prakash et al., 2009). How-
ver the most common medium used for oxytocin detection is
lasma (of 50 papers reviewed using one or multiple substrates,
 = 39 plasma, n = 9 saliva, n = 8 urine, n = 6 cerebro-spinal ﬂuid, n = 5
erum and n = 2 milk). Despite its potential as a tool for investigat-
ng the expression of social and maternal behaviour in mammalian
pecies, few analysis protocols for detecting oxytocin concentra-
ions in plasma taken from wild populations or species have been
alidated.
The effect of capture and sampling procedure on detected
lasma oxytocin concentrations of wild mammalian species has
ever been investigated in any prior study, and it is vital to
nsure that abnormal concentrations of oxytocin are not being
enerated during this potentially stressful process. Oxytocin is doc-
mented to be released into circulation during extreme stressors
uch as restraint over an extended time period in rodents (Grippo
t al., 2009; Pournajaﬁ and Carter, unpublished observations) and
s hypothesised to occur during procedures such as injections
Devarajan and Rusak, 2004). Therefore any attempt to study basal
evels of this hormone in wild populations, which must be manu-
lly or chemically restrained during the sampling procedure, must
e accompanied by investigation of whether oxytocin is released
hen sampling occurs.
Even with the increasing number of studies using plasma to
nvestigate oxytocin, there is still contention about the appro-
riate way to collect and analyse samples accurately, and
here has been a call for new research into reliable, accu-
ate methodologies for investigators to utilise in future research
McCullough et al., 2013). The majority of studies published use
n enzyme-linked immunosorbent assay (ELISA) kit manufactured
y Assay Designs Inc. (Ann Arbor, MI,  USA). However despite this
anufacturer providing a protocol for collection and preparationence Methods 226 (2014) 73–79
prior to analysis, there is huge variation between studies in the
methods researchers actually employ (of 39 papers, n = 3 unex-
tracted serum, n = 13 extracted plasma, n = 17 unextracted plasma
and n = 6 did not specify if extraction was used. For vacutainer type
used in sampling, n = 12 ethylenediaminetetraacetic acid (EDTA)
vacutainers, n = 10 lithium heparin vacutainers and n = 14 did not
specify what vacutainer was used). In addition to the varying anal-
ysis protocols, there is disagreement in the literature over whether
oxytocin concentrations measured in raw plasma are correlated
with those in extracted samples, and how accurate the use of raw
plasma is (McCullough et al., 2013). Currently some studies rely on
the hypothesis that there is a direct relationship between oxytocin
concentrations determined in extracted and raw samples (Hoge
et al., 2012), provide data showing a correlation between oxytocin
levels in raw and extracted serum samples (Michopoulos et al.,
2011) or have validated oxytocin ELISAs for rodent species using
raw plasma samples (Kramer et al., 2004). However, two papers
to date have directly tested the beneﬁts of extracting plasma sam-
ples prior to analysis, with both recommending the use of solid
phase extraction with C18 Sep-Pak columns (Bachem, San Car-
los, CA) as the best method to gain accurate detection levels for
oxytocin in plasma (Szeto et al., 2011; Cool and DeBrosse, 2003).
Szeto et al. (2011) report no correlation between oxytocin concen-
trations measured in raw plasma and those in extracted plasma,
and call for further work to be carried out in order to develop
reliable methods for oxytocin analysis. Additionally the large dis-
crepancy between reported oxytocin concentrations detected in
raw and extracted plasma (>100 pg/ml and <30 pg/ml, respectively,
reviewed in Szeto et al., 2011) make comparisons across stud-
ies with different methodologies impossible and interpretation of
which values most accurately reﬂect true oxytocin concentrations
difﬁcult.
This study investigates oxytocin plasma concentrations for the
ﬁrst time in two marine mammal  species, the grey seal and harbour
seal, and assesses how the measured concentration of oxytocin in
plasma is affected by the type of anticoagulant used during col-
lection, the handling process of the individual being sampled and
subsequently whether the plasma is extracted prior to analysis. The
relationship between raw and extracted oxytocin concentrations
detected was also investigated in order to determine whether one
can be used to accurately predict the other. This work was con-
ducted during the development of the best protocol for detecting
oxytocin accurately in phocid seals and was conducted as part of a
larger study on phocid reproductive behaviour and physiology.
2. Methods
2.1. Ethics statement
This study used captive harbour and grey seals held under
UK Home Ofﬁce licence at the Sea Mammal  Research Unit in
St Andrews, Scotland. Capture and handling procedures were
performed under Home Ofﬁce project licence #60/4009 and con-
formed to the UK Animals (Scientiﬁc Procedures) Act, 1986. All
research was  approved ethically by the University of St Andrews
Animal Welfare and Ethics Committee.
2.2. Study animals
Three seals provided blood samples for the comparison of vacu-
tainer type and extraction protocol. Samples were collected over
the period the seals were within the facility. The ﬁrst was an adult
male harbour seal of unknown age, brought into the facility on
10.02.11 from the Eden River, Scotland and released in November
2011. The other two were immature grey seals of known age, one
male and one female. Both of these were born in November of the
2011 breeding season on the Isle of May, Scotland and brought
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nto captivity on 06.12.11 at approximately one month of age. The
emale was released in October 2012 and the male in December
012. Additionally, a two-year old captive male harbour seal from
he Moray Firth, Scotland kept from 01.10.10 until 29.10.11, was
sed to generate a dataset on the clearance rate of oxytocin in
hocid seals using extracted and un-extracted samples.
.3. Plasma sampling and analysis
Plasma samples were taken at approximately monthly intervals
hroughout the period of captivity (n = 27). A sample collected using
eparin vacutainers was collected in all 27 sampling opportuni-
ies; however during two of the sampling opportunities it was  not
ossible additionally to collect an EDTA sample, giving 25 match-
ng EDTA plasma samples and a total number of 52 samples to
ompare to each other. To obtain a plasma sample, animals were
aptured and physically restrained, additionally animals over eight
onths of age were chemically immobilised using Zoletil® (Virbac).
amples were drawn from the extradural vein into either 10 ml
ithium heparin or EDTA vacutainers without addition of aprotinin
nd stored on ice until they could be spun and frozen at −20 ◦C
CS Carter 2010 personal communication). While the ELISA proto-
ol recommends freezing samples at −70 ◦C, this work was  part
f a larger project to determine the viability of samples obtained
rom a ﬁeld site where only a −20 ◦C freezer was  available. This
tudy attempted to obtain all samples within ﬁve minutes of the
nitial disturbance to the animal as the reported short half life of
xytocin in plasma (Cool and DeBrosse, 2003) would suggest that
low sampling would not give a representative sample. The time
aken to obtain a sample, and if chemical immobilisation was used,
as recorded to account for these variables in the analysis. At each
ampling event four 10 ml  vacutainers of plasma (two of each type)
ere taken. Plasma was  then analysed for oxytocin using an ELISA
Assay Designs Inc., Ann Arbor, MI,  USA) with each sample under-
oing solid-phase extraction using Sep-Pak C18 columns (Szeto
t al., 2011; Cool and DeBrosse, 2003) prior to analysis following
he manufacturer’s instructions with the following modiﬁcations.
irst it was necessary to extract from 3 ml  of plasma to allow use
f the most sensitive part of the assay curve for determining con-
entrations of oxytocin. Second all samples had to be centrifuged
fter acidiﬁcation for thirty minutes rather than ﬁfteen; otherwise
here was a risk that the plasma samples would block the Sep-Pak
olumns used to extract the peptide due to the high lipid and albu-
in  concentrations present in phocid plasma (Hall, 1998). Extracts
ere then frozen until analysed, whereupon they were rehydrated
ccording to the assay instructions and run on the ELISA plate. Both
aw plasma and extracted plasma were analysed for all 52 samples
ollected during analysis, giving a total sample size of 104 samples
or this study. The plate was read using a BioTek ELx800 reader and
he standard curve and assay results for all plates were then ﬁtted
sing the calibFit package (Haaland et al., 2011) in R version 2.9.2
R Development Core Team, 2008). Recovery rates for the extrac-
ion and ELISA procedure were 107% (n = 10), intra-assay coefﬁcient
f variance for this assay was 4.6% and inter-assay coefﬁcient of
ariance over the seven plates used in this study was 4%.
.4. Clearance trial
For the duration of the 1 hour trial, the study animal was
aptured and chemically immobilised using Zoletil® (Virbac). A
aseline sample was drawn from the extradural vein into 10 ml
ithium heparin vacutainers, and then 3.96 g oxytocin (0.022 ml  of
.18 mg/ml  Oxytocin-S, Intervet UK Ltd. with 0.128 ml  saline solu-
ion) was injected intravenously to create a hormone spike in the
lasma. Serial samples were then taken every minute for the ﬁrst
ve minutes of the trial, then every ﬁve minutes until 20 minutes
ost-injection, and ﬁnally every ten minutes until one hourence Methods 226 (2014) 73–79 75
post-injection. Samples were then stored, spun, frozen and ana-
lysed as described above, generating clearance curves for both
extracted and raw versions of the same samples. The plasma clear-
ance rate (CL) for both raw and extracted plasma samples from the
same clearance trail were calculated using the following equation
(Morin et al., 2008):
CL = D
AUC
where area under curve (AUC) is the area under the curve generated
in the GAMs detailed below describing the relationship between
plasma oxytocin concentrations and time post injection and D is
the initial bolus of oxytocin injected in picograms (pg).
2.5. Statistical analysis
All analyses were performed using the statistical package R
2.15.0 (R Development Core Team, 2012). Generalised additive
mixed models (GAM) (Wood, 2006a) were used to take into account
variability in oxytocin generated by species, sex, the day of year
the samples were taken, and the analysis protocol used (EDTA
extracted, EDTA raw, heparin extracted and heparin raw). The mod-
els had a gamma  error distribution with a log link and were ﬁtted
using the multiple generalised cross validation library mgcv (Wood,
2012). As any variation with ‘day of year’ (DOY) is unlikely to be
linear, this was ﬁtted as a smooth function (Wood, 2006b). Dif-
ferences between species and sex in the seasonal pattern were
examined by ﬁtting additional smooth functions. The smoothing
parameters were set by maximum likelihood to reduce the risk of
overﬁtting associated with other methods (Wood, 2011). All other
variables were ﬁtted as ﬁxed effects. Backwards stepwise elimi-
nation was carried out by using the Akaike information criterion
(AIC) to identify the best model of the data and QQ and residual
plots were examined to check the adequacy of the models. On this
basis, all smooths were removed from the model, and DOY was
removed entirely, simplifying the model into a generalised linear
model (GLM) and leaving three ﬁxed effects (species, sex and anal-
ysis protocol) which produced the best performing model.
Two  separate GLMs were used to investigate any relationship
between time taken to obtain a plasma sample, the use of chemi-
cal immobilisation or physical restraint and vacutainer type on the
oxytocin concentrations detected in raw and extracted plasma. This
could not be included in the ﬁrst GLM as some values were missing
from one individual’s data, which would have reduced the number
of samples included in the analysis above. The time in minutes it
took to obtain a plasma sample from the initial disturbance to the
individual, the type of vacutainer used for sample collection, what
form of restraints (physical or chemical) were used for the proce-
dure and an interaction term for sampling time/restraint type were
ﬁtted as ﬁxed effects and a gamma  error distribution with a log link
was used. Backwards stepwise elimination was  carried out by using
the Akaike information criterion (AIC) to identify the best model of
the data and QQ and residual plots were examined to check the
adequacy of the models.
To investigate any correlations between oxytocin concentra-
tions detected in extracted and raw plasma samples (n = 52), two
GLM was  used to model the relationship between the two meas-
ures taken with heparin (n = 27) and EDTA (n = 25) vacutainers
separately and to predict extracted values of oxytocin from con-
centrations detected in raw samples. All GLM ﬁts were ﬁtted with
gamma  error distributions with log links and were checked with
diagnostic plots and AIC scores to determine the best ﬁts for the
data.Non-linear and GAM approaches were investigated to quantify
the clearance curves generated from the IV oxytocin injection. The
GAM approach was  determined to be the most suitable for compar-
ing the quality of the two clearance curves, and GAMs were made
76 K.J. Robinson et al. / Journal of Neuroscience Methods 226 (2014) 73–79
Table 1
Fixed effect variables from the GLM of the effect of analysis protocol on detected
oxytocin concentration, their estimates, standard errors and p values.
GLM variable Estimate Standard error p-Value
Analysis protocol (heparin extracted) 0.03 0.087 0.71
Analysis protocol (heparin raw) 3.66 0.087 <0.001
Analysis protocol (EDTA raw) 4.21 0.088 <0.001
Sex  −0.18 0.072 0.012
Species −0.53 0.077 <0.001
Table 2
Mean concentrations of oxytocin detected (pg/ml) in phocid plasma according to
vacutainer type used to collect the sample and extraction protocol with standard
errors.
EDTA vacutainers Heparin vacutainers
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Table 4
Fixed effect variables from the GLM of the effect of time to sample, the type of
restraint and vacutainer type on detected oxytocin concentrations in raw plasma,
their estimates, standard errors and p values.
GLM variable Estimate Standard error p-Value
Time to obtain sample −0.53 0.18 0.007
Type of restraint (chemical) −0.39 0.31 0.21
Vacutainer type (heparin) −0.57 0.11 <0.001
Interaction term between time 0.5 0.18 0.01
cessful at producing an accurate clearance curve compared to one
generated with extracted plasma (percentage deviance explained:
raw plasma: 30.7%, extracted plasma: 85.2%). In addition the con-
ﬁdence intervals were much wider around the ﬁtted curve for theExtracted plasma 8.1 ± 0.6 8.3 ± 0.66
Raw plasma 543.2 ± 43.6 300.9 ± 19.6
or both extracted results and raw results. Both used one ﬁxed effect
minutes post oxytocin injection) and as this variable was not linear
t was ﬁtted as a smooth function (Wood, 2006b) with smoothing
arameters set by maximum likelihood (Wood, 2011).
. Results
.1. Causes of variability in oxytocin detection in seals
Of the variables tested, the GLM model showed that anal-
sis protocol (n = 104 GLM, F3,101 = 934.8, p < 0.001) sex (n = 104
LM, F1,103 = 0.011, p = 0.01) and species (n = 104 GLM, F1,103 = 46.9,
 < 0.001) signiﬁcantly affected the oxytocin detected in samples
Table 1). There was no signiﬁcant difference between extracted
amples taken with EDTA (mean = 8.1 ± 0.6 pg/ml) or heparin
mean = 8.3 ± 0.6 pg/ml) vacutainers (p = 0.71). However there were
igniﬁcant differences between all extracted and raw plasma proto-
ols regardless of vacutainer type (p < 0.001) and between samples
nalysed raw taken using EDTA (mean = 543.2 ± 43.6 pg/ml)
nd heparin (mean = 300.9 ± 19.6 pg/ml) vacutainers (p < 0.001)
Table 2).
.2. The effect of sampling time and restraint protocol on
xytocin detected
No relationship was found between oxytocin concentration
etected in extracted plasma and the use of chemical or physical
estraint in the capture process (n = 36 GLM, F1,35 = 0.73, p = 0.27),
ime taken to obtain a sample from ﬁrst contact (n = 36 GLM,
1,35 = 1.03, p = 0.14), the interaction term for time to sample and
ype of restraint (n = 36 GLM, F1,35 = 2.41, p = 0.13) or vacutainer type
n = 36 GLM, F1,35 = 0.61, p = 0.39) (Table 3).
There were signiﬁcant differences in detected oxytocin concen-
rations in raw plasma with the time taken to obtain a sample
able 3
ixed effect variables from the GLM of the effect of time to sample, the type of
estraint and vacutainer type on detected oxytocin concentrations in extracted
lasma, their estimates, standard errors and p values.
GLM variable Estimate Standard error p-Value
Time to obtain sample 0.28 0.18 0.14
Type of restraint 0.34 0.31 0.27
Vacutainer type 0.09 0.11 0.39
Interaction term between time
to sample and type of
restraint
−0.29 0.18 0.13to sample and type of
restraint
from ﬁrst contact (n = 36 GLM, F1,35 = 0.62, p = 0.007), the interaction
term for time to sample and type of restraint (physical or chemical)
(n = 36 GLM, F1,35 = 0.73, p = 0.01) and vacutainer type (n = 36 GLM,
F1,35 = 28.8, p < 0.001) (Table 4).
3.3. Correlations between oxytocin detected in raw and extracted
plasma
No relationship was  found between oxytocin concentrations
detected in raw and extracted plasma samples taken with hep-
arin (n = 27 GLM, F1,26 = 1.24, p = 0.25) or EDTA vacutainers (n = 25
GLM, F1,24 = 2.47, p = 0.12) (Fig. 1). Furthermore, when the best
model was used to generate predicted oxytocin concentrations in
extracted samples from a subset of raw values, the resulting dataset
(mean = 2.1 ± 0.008 pg/ml) was signiﬁcantly different from the true
values (mean = 8.2 ± 0.4 pg/ml) when analysed using a Welch two
sample T test (t(15) = 8.2, p < 0.001).
3.4. Clearance rate of oxytocin calculated using raw and
extracted samples
Both GAM models showed that in raw and extracted plasma
there was a signiﬁcant decline in oxytocin over time towards the
basal level (n = 13 in each GAM, for both p < 0.001). However the
oxytocin values detected using raw plasma were much less suc-Fig. 1. Scatter plot showing the oxytocin concentrations detected in plasma samples
that were analysed both raw and with extraction prior to assay. Samples collected
in  EDTA vacutainers are shown in black () and samples collected in heparin vacu-
tainers are shown in white (©).
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Fig. 2. Clearance curves for one individual given a single IV oxytocin dose, generated
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esing both raw (red, the top solid line) and extracted (blue, the bottom solid line)
lasma, with conﬁdence intervals (dashed). (For interpretation of the references to
olor in this ﬁgure legend, the reader is referred to the web version of the article.)
aw results (Fig. 2). The plasma clearance rate calculated using the
urve generated with extracted plasma was 0.035 L/min/kg, while
he plasma clearance rate calculated using the curve generated with
aw plasma was 0.004 L/min/kg.
. Discussion
This study has determined successfully for the ﬁrst time plasma
xytocin concentrations in two novel mammalian species, the grey
eal and harbour seal. Furthermore, it has demonstrated clear and
ubstantial differences in the oxytocin concentrations measured
n phocid plasma samples depending on the protocol used to col-
ect and analyse them. The largest differences were between raw
nd extracted plasma: raw samples produced oxytocin measures
everal hundreds times higher than extracted plasma. Importantly,
o relationship was detected between the raw and extracted oxy-
ocin concentrations. Such a relationship would be necessary for the
rediction of one based on the other. Samples analysed raw were
igniﬁcantly inﬂuenced by the time it took to obtain a blood sample
nd by the type of restraints used, while extracted samples were not
ffected by these sources of variation. Finally samples taken with
DTA vacutainer tubes had signiﬁcantly higher concentrations of
xytocin than heparin tubes when run raw on a plate, but when
xtracted there was no difference between the two. Therefore the
esign of a study protocol will have a major impact on the results
enerated, which must be taken into account when analysing and
nterpreting the data.
.1. Raw versus extracted plasma
The results show clearly that the concentration of oxytocin
etected in raw plasma samples is substantially higher than that
n extracted samples (mean oxytocin extracted EDTA: 8.1 pg/ml,
xtracted heparin: 8.3 pg/ml, raw EDTA: 543.2 pg/ml, raw heparin:
00.9 pg/ml). These concentrations represent the ﬁrst published
ata on plasma oxytocin concentrations found in a phocid seal, or
ny marine mammal  species, and are comparable to both extracted
nd raw plasma concentrations reported in the literature for other
ammalian species. Humans have been reported to have basal
lasma oxytocin concentrations ranging between 0.1–23 pg/ml in
xtracted plasma and 99–405 pg/ml in raw plasma (reviewed inence Methods 226 (2014) 73–79 77
Szeto et al., 2011) and rats have mean oxytocin concentrations of
6.8 pg/ml in extracted plasma (Langraf, 1981) and concentrations
ranging from 78.9–580 pg/ml in raw plasma (Carter et al., 2007;
Martínez-Lorenzana et al., 2008). Szeto et al. (2011) detected the
same contrast in concentrations measured using raw and extracted
plasma while evaluating radioimmunoassay (RIA) and ELISA proto-
cols for oxytocin analysis and used high performance liquid phase
chromatography (HPLC) to investigate the components of raw
plasma, enabling the identiﬁcation of several oxytocin immunore-
active species in raw plasma. This accounts for the large difference
between the concentrations of oxytocin measured in raw and
extracted samples, and at least one of the additional immunore-
active species was  identiﬁed as a degradation product of oxytocin.
It is vital that any studies using raw plasma as the medium for
analysis take this into account, as any results obtained will not be
a reﬂection of oxytocin alone, but rather of an unknown number of
other metabolic processes generating these reactive molecules in
the blood.
The potential differences a study can incur in their results just
by using raw or extracted plasma is well illustrated by the dif-
ferent plasma clearance rates generated from the clearance trial
in this study. The plasma clearance rate for seals detected with
extracted plasma (0.035 L/min/kg) is comparable to the existing
values published for the clearance rate of oxytocin in other mam-
malian species detected with RIAs (0.027 L/kg/min in human men
and 0.021 L/min/kg in human women  (Leake et al., 1980), between
0.025 and 0.085 L/min/kg in rats depending on dose (Morin et al.,
2008), and 0.016 L/min/kg in baboons (Kowalski et al., 1998)). How-
ever the plasma clearance rate generated by the raw plasma data
(0.004 L/min/kg) is much slower than the rate from extracted sam-
ples and other published work due to the high AUC value generated
from the raw plasma clearance curve (Fig. 2).
A difference between the two concentrations detected does not
immediately rule out using information about one to infer the con-
centration of the other. If the other reactive species measured in the
ELISA in raw samples are products of oxytocin metabolism then it
could be theorised that raw levels would still give an indication
of an individual’s oxytocin activity in the blood. There have been
studies that detected such a correlation, such as Michopoulos et al.
(2011) and others that found no such link, such as Szeto et al. (2011).
The current study was not able to ﬁnd any correlation between the
raw and extracted samples, and in addition found that regression
models built on such data had poor predictive power for gener-
ating accurate extracted oxytocin levels from raw measurements.
When analysing a set of serial samples taken during a clearance
trial, the data generated from extracted samples produced a curve
which accurately represented the decay rate. The data generated
from raw samples, while still detecting an overall fall in oxytocin
levels, could not have a clearance curve ﬁtted to it that accounted
for more than 30% of the variation in the data. Therefore our ﬁndings
are in agreement with Szeto et al.’s work, that raw plasma cannot
be used to accurately analyse oxytocin levels. However, Michopou-
los et al. used serum rather than plasma for their analysis, which
may  have produced differences in the metabolites maintained or
denatured during collection and storage. In addition the datasets
used here and by Szeto et al. to generate the regressions and corre-
lations are larger (n = 52 and n = 39, respectively) than the one used
by Michopoulos et al. (n = 11) and therefore may  have obtained a
more representative dataset to work from. Michopoulos et al. also
do not give details of the correlation model used to generate their
results, preventing direct comparisons between the varying meth-
ods of statistical analysis used in the current study (GLM) and by
Szeto et al. (Spearman rank correlation).
Therefore we caution that studies using raw plasma with the
Assay Designs ELISA kit are unlikely to report oxytocin alone and
additionally cannot accurately infer this data from their results.
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.2. Heparin versus EDTA vacutainers
The current study shows that if plasma is extracted prior to
nalysis, the particular anticoagulant in the vacutainer makes no
ifference to the concentration of oxytocin detected. This allows
tudies using extracted plasma to be comparable, regardless of
acutainer choice. However when analysing raw plasma, EDTA
ubes contain almost double the concentration of oxytocin com-
ared to heparin tubes collected samples (mean oxytocin EDTA:
43.2 pg/ml, heparin: 300.9 pg/ml). Other studies analysing dif-
erent biological compounds in human samples have reported
imilar differences between the anticoagulants (Dong et al., 2010;
onzalez-Covarrubias et al., 2013) while for some peptides there
ppears to be no difference (Varo et al., 2006). The protocol instruc-
ions for the Assay Designs ELISA do state that the chelators in
DTA might affect the activity of the conjugate used in the kit
Enzo Life Sciences Oxytocin ELISA kit Manual 2012). The conju-
ate is responsible for reacting with the p-nitrophenylphosphate
ubstrate to generate a yellow colour, which indicates a low con-
entration of oxytocin as the intensity of the colour increases. If
his function was  impaired due to EDTA presence then no yel-
ow colour would be generated and a false positive would occur.
eparin vacutainers work by potentiating the action of antithrom-
in (Chuang et al., 2001), which inactivates coagulation proteins
ather than using chelators to bind ions, and this may  account for
he difference in results. This highlights the importance of fully
nvestigating the consequences of any deviation from the kit manu-
acturer’s instructions as the kit protocol recommends using EDTA
ubes for collection with extracting prior to analysis. Therefore the
iscrepancy between the two tube types must be taken into account
hen designing a study, interpreting the results and comparing
hem across studies, and can be avoided completely if samples are
xtracted.
.3. Inﬂuence of other variables
Several variables were analysed alongside protocol type to
nsure all sources of variation in the dataset could be identiﬁed.
he time to obtain a plasma sample and using physical or chemical
estraints had no effect on the oxytocin detected in extracted sam-
les, but signiﬁcantly impacted on the concentrations detected in
aw plasma. Oxytocin has been linked to restraint stress in rodents
Grippo et al., 2009) and is hypothesised to rise in response to high
ortisol levels. However in previous studies only long term cap-
ure and restraint generated peaks in oxytocin (CS Carter, personal
ommunication) and our results support this. As there were no sig-
iﬁcant changes in oxytocin concentration with time in extracted
amples, it should be possible to obtain samples in future stud-
es that allow detection of basal oxytocin concentrations from wild
nimals captured either manually or using a chemical immobiliser
roviding samples are extracted prior to analysis.
The individual’s species and sex were both signiﬁcant sources
f variation in this study, while time of year was not. As this work
ncludes few individuals, and no repeats of any species/sex com-
ination were possible, stochastic differences between them are
ntirely plausible, and having access to a larger number of ani-
als would have allowed us to examine this variation to determine
ts validity. Despite, there being signiﬁcant variation in individ-
al’s oxytocin concentration, the differences generated by the four
rotocols are greater still and are present at the highest level of
igniﬁcance in the model.
Finally this study focused on the variation in oxytocin generated
y extraction protocol and vacutainer choice, and did not speciﬁ-
ally test for variation generated by differing storage temperatures
r the use of aprotinin to stabilise the peptide. These two  vari-
bles were kept consistent across the samples in this study, withence Methods 226 (2014) 73–79
all plasma stored at −20 ◦C with no addition of aprotinin. The coef-
ﬁcient of variance in this study remained consistently below 5%
across two years of analysis, indicating that degradation of oxy-
tocin in samples stored at −20 ◦C without the use of aprotinin was
negligible. The inﬂuence of storage temperature and additional
inhibitors on oxytocin concentration detected would be an area
worthy of future study, as protocols in the literature vary on these
points along with vacutainer type and use of extraction. The major-
ity of studies published freeze at the recommended −70 ◦C with a
minority using −20 ◦C or below (Scantamburlo et al., 2007; Yayou
et al., 2010), yet this study and several others (Szeto et al., 2011;
van der Post et al., 1997) indicate that oxytocin may  be more stable
in warmer storage temperatures than is thought currently. The use
of aprotinin or any inhibitor post-sampling is extremely diverse
in the literature, with as many studies using aprotinin (Feldman
et al., 2010a,b; Skrundz et al., 2011; Weisman et al., 2013; Hoffman
et al., 2012) as not (Scantamburlo et al., 2007; Yayou et al., 2010;
Szeto et al., 2011; Deisenhammer et al., 2012; Hoge et al., 2012).
The impact of these additional inconsistencies between studies in
oxytocin analysis protocol would beneﬁt from further investiga-
tion.
In conclusion, the protocol followed when collecting and
analysing plasma for oxytocin does have a signiﬁcant impact on
the results generated and experimental design should be carefully
considered when planning research in this area. The concentrations
of basal plasma oxytocin in phocid seals are consistent with those
detected in all mammal  species studied to date in both extracted
and raw plasma, and the clearance rate for this hormone in phocids
is also comparable to that found in humans (Leake et al., 1980), rats
(Morin et al., 2008) and primates (Kowalski et al., 1998). Therefore
despite being novel species to this ﬁeld, it appears that phocid seals
represent a typical mammalian system in terms of plasma oxytocin.
Therefore future work should use methods which generate reli-
able, repeatable measures of plasma oxytocin, as well as developing
protocols for using other peripheral substrates such as saliva and
urine. Due to their non-invasive nature, such mediums are becom-
ing more popular but the methodologies to utilise them have their
critics (Horvat-Gordon et al., 2005). Without a ﬁrm knowledge of
what experimental variables researchers may  inadvertently intro-
duce into a study, it will be extremely difﬁcult to decipher the role
of this neuropeptide in human and animal social and reproductive
systems.
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